Show simple item record

dc.contributor.authorNavarro Sarabia, Federico
dc.contributor.authorRuiz Montesinos, Dolores
dc.contributor.authorHernández, Blanca
dc.contributor.authorNavarro Compán, Victoria
dc.contributor.authorMarsal, Sara
dc.contributor.authorBarcelo, Mireia
dc.contributor.authorPérez Pampín, Eva
dc.contributor.authorGómez-Reino Carnota, Juan Jesús
dc.date.accessioned2020-06-12T08:40:51Z
dc.date.available2020-06-12T08:40:51Z
dc.date.issued2009
dc.identifier.citationNavarro-Sarabia, F., Ruiz-Montesinos, D., Hernandez, B. et al. DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. BMC Musculoskelet Disord 10, 91 (2009)
dc.identifier.urihttp://hdl.handle.net/10347/22952
dc.description.abstractIntroduction No definitive data are available regarding the value of switching to an alternative TNF antagonist in rheumatoid arthritis patients who fail to respond to the first one. The aim of this study was to evaluate treatment response in a clinical setting based on HAQ improvement and EULAR response criteria in RA patients who were switched to a second or a third TNF antagonist due to failure with the first one. Methods This was an observational, prospective study of a cohort of 417 RA patients treated with TNF antagonists in three university hospitals in Spain between January 1999 and December 2005. A database was created at the participating centres, with well-defined operational instructions. The main outcome variables were analyzed using parametric or non-parametric tests depending on the level of measurement and distribution of each variable. Results Mean (± SD) DAS-28 on starting the first, second and third TNF antagonist was 5.9 (± 2.0), 5.1 (± 1.5) and 6.1 (± 1.1). At the end of follow-up, it decreased to 3.3 (± 1.6; Δ = -2.6; p > 0.0001), 4.2 (± 1.5; Δ = -1.1; p = 0.0001) and 5.4 (± 1.7; Δ = -0.7; p = 0.06). For the first TNF antagonist, DAS-28-based EULAR response level was good in 42% and moderate in 33% of patients. The second TNF antagonist yielded a good response in 20% and no response in 53% of patients, while the third one yielded a good response in 28% and no response in 72%. Mean baseline HAQ on starting the first, second and third TNF antagonist was 1.61, 1.52 and 1.87, respectively. At the end of follow-up, it decreased to 1.12 (Δ = -0.49; p < 0.0001), 1.31 (Δ = -0.21, p = 0.004) and 1.75 (Δ = -0.12; p = 0.1), respectively. Sixty four percent of patients had a clinically important improvement in HAQ (defined as ≥ -0.22) with the first TNF antagonist and 46% with the second. Conclusion A clinically significant effect size was seen in less than half of RA patients cycling to a second TNF antagonist
dc.description.sponsorshipThe study was partially funded by a grant of BMS, Spain, and by RETICS Program, RD08/0075 (RIER) from the Instituto de Salud Carlos III (ISCIII), within the VI PN de I+D+I 2008–2011
dc.language.isoeng
dc.publisherBMC
dc.rights© 2009 Navarro-Sarabia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
dc.rights.urihttp://creativecommons.org/licenses/by/2.0
dc.subjectRheumatoid Arthritis Patient
dc.subjectHerpes Zoster
dc.subjectRetention Rate
dc.subjectTocilizumab
dc.subjectAbatacept
dc.titleDAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists
dc.typeinfo:eu-repo/semantics/article
dc.identifier.DOI10.1186/1471-2474-10-91
dc.relation.publisherversionhttps://doi.org/10.1186/1471-2474-10-91
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.e-issn1471-2474
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina
dc.description.peerreviewedSI


Files in this item

application/pdf
Name: 2009_bmcmusculoskeletdisord_navarro_das.pdf
Size: 266.3 Kb
Format: PDF


Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2009 Navarro-Sarabia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Except where otherwise noted, this item's license is described as  © 2009 Navarro-Sarabia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited





Harvesters:Useful links:
Universidade de Santiago de Compostela | Teléfonos: +34 881 811 000 e +34 982 820 000 | Contact Us | Send Feedback